vs
Apellis Pharmaceuticals, Inc.（APLS）与Kiniksa Pharmaceuticals International, plc（KNSA）财务数据对比。点击上方公司名可切换其他公司
Kiniksa Pharmaceuticals International, plc的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$202.1M vs $199.9M），Kiniksa Pharmaceuticals International, plc净利率更高（7.0% vs -29.5%，领先36.5%），Kiniksa Pharmaceuticals International, plc同比增速更快（65.0% vs -5.9%），Kiniksa Pharmaceuticals International, plc自由现金流更多（$53.3M vs $-14.3M），过去两年Kiniksa Pharmaceuticals International, plc的营收复合增速更高（59.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Kiniksa Pharmaceuticals International plc是一家全球性生物制药企业，专注于发现、开发和商业化针对自身免疫性疾病、炎症性疾病及罕见病的靶向治疗药物，服务北美、欧洲、亚洲等主要市场的未被满足的临床需求。
APLS vs KNSA — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $202.1M |
| 净利润 | $-59.0M | $14.2M |
| 毛利率 | — | 89.6% |
| 营业利润率 | -25.6% | 9.8% |
| 净利率 | -29.5% | 7.0% |
| 营收同比 | -5.9% | 65.0% |
| 净利润同比 | -62.2% | 259.8% |
| 每股收益（稀释后） | $-0.40 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $202.1M | ||
| Q3 25 | $458.6M | $180.9M | ||
| Q2 25 | $178.5M | $156.8M | ||
| Q1 25 | $166.8M | $137.8M | ||
| Q4 24 | $212.5M | $122.5M | ||
| Q3 24 | $196.8M | $112.2M | ||
| Q2 24 | $199.7M | $108.6M | ||
| Q1 24 | $172.3M | $79.9M |
| Q4 25 | $-59.0M | $14.2M | ||
| Q3 25 | $215.7M | $18.4M | ||
| Q2 25 | $-42.2M | $17.8M | ||
| Q1 25 | $-92.2M | $8.5M | ||
| Q4 24 | $-36.4M | $-8.9M | ||
| Q3 24 | $-57.4M | $-12.7M | ||
| Q2 24 | $-37.7M | $-3.9M | ||
| Q1 24 | $-66.4M | $-17.7M |
| Q4 25 | — | 89.6% | ||
| Q3 25 | — | 88.8% | ||
| Q2 25 | — | 88.1% | ||
| Q1 25 | — | 87.0% | ||
| Q4 24 | — | 85.4% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 88.7% | ||
| Q1 24 | — | 86.7% |
| Q4 25 | -25.6% | 9.8% | ||
| Q3 25 | 48.7% | 13.3% | ||
| Q2 25 | -18.6% | 12.9% | ||
| Q1 25 | -50.0% | 9.6% | ||
| Q4 24 | -12.3% | -15.7% | ||
| Q3 24 | -24.0% | -8.6% | ||
| Q2 24 | -14.7% | -0.1% | ||
| Q1 24 | -36.0% | -20.7% |
| Q4 25 | -29.5% | 7.0% | ||
| Q3 25 | 47.0% | 10.2% | ||
| Q2 25 | -23.6% | 11.4% | ||
| Q1 25 | -55.3% | 6.2% | ||
| Q4 24 | -17.1% | -7.3% | ||
| Q3 24 | -29.2% | -11.3% | ||
| Q2 24 | -18.9% | -3.6% | ||
| Q1 24 | -38.5% | -22.2% |
| Q4 25 | $-0.40 | $0.18 | ||
| Q3 25 | $1.67 | $0.23 | ||
| Q2 25 | $-0.33 | $0.23 | ||
| Q1 25 | $-0.74 | $0.11 | ||
| Q4 24 | $-0.30 | $-0.11 | ||
| Q3 24 | $-0.46 | $-0.18 | ||
| Q2 24 | $-0.30 | $-0.06 | ||
| Q1 24 | $-0.54 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $414.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $567.6M |
| 总资产 | $1.1B | $763.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $414.1M | ||
| Q3 25 | $479.2M | $352.1M | ||
| Q2 25 | $370.0M | $307.8M | ||
| Q1 25 | $358.4M | $268.3M | ||
| Q4 24 | $411.3M | $243.6M | ||
| Q3 24 | $396.9M | $223.8M | ||
| Q2 24 | $360.1M | $218.8M | ||
| Q1 24 | $325.9M | $213.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $567.6M | ||
| Q3 25 | $401.2M | $535.4M | ||
| Q2 25 | $156.3M | $495.0M | ||
| Q1 25 | $164.2M | $457.5M | ||
| Q4 24 | $228.5M | $438.4M | ||
| Q3 24 | $237.1M | $437.0M | ||
| Q2 24 | $264.3M | $435.1M | ||
| Q1 24 | $266.7M | $431.9M |
| Q4 25 | $1.1B | $763.6M | ||
| Q3 25 | $1.1B | $712.3M | ||
| Q2 25 | $821.4M | $661.1M | ||
| Q1 25 | $807.3M | $599.3M | ||
| Q4 24 | $885.1M | $580.6M | ||
| Q3 24 | $901.9M | $555.3M | ||
| Q2 24 | $904.5M | $542.4M | ||
| Q1 24 | $831.9M | $519.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $53.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $53.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 26.4% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 3.80× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $136.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $53.9M | ||
| Q3 25 | $108.5M | $33.7M | ||
| Q2 25 | $4.4M | $28.1M | ||
| Q1 25 | $-53.4M | $22.3M | ||
| Q4 24 | $19.4M | $18.8M | ||
| Q3 24 | $34.1M | $-2.2M | ||
| Q2 24 | $-8.3M | $5.2M | ||
| Q1 24 | $-133.0M | $4.0M |
| Q4 25 | $-14.3M | $53.3M | ||
| Q3 25 | $108.3M | $33.0M | ||
| Q2 25 | $4.4M | $27.9M | ||
| Q1 25 | $-53.4M | $22.2M | ||
| Q4 24 | $19.3M | $18.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | $3.9M |
| Q4 25 | -7.1% | 26.4% | ||
| Q3 25 | 23.6% | 18.2% | ||
| Q2 25 | 2.5% | 17.8% | ||
| Q1 25 | -32.0% | 16.1% | ||
| Q4 24 | 9.1% | 15.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | 4.9% |
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | 3.80× | ||
| Q3 25 | 0.50× | 1.83× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 2.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
KNSA
暂无分部数据
